Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers
<b>Background</b>: Psoriasis is a skin disease characterized by the presence of erythematous, scaly plaques on the extensor surfaces of the body. Treatment varies according to the stage of the disease, with the most severe cases being treated with biologic treatments that differ in effic...
Saved in:
Main Authors: | Andrea Rodríguez-Lopez, María Martínez-Sendino, Rocío Prieto-Pérez, Paula Soria-Chacartegui, Eva González-Iglesias, Mario Aparicio-Domínguez, Sonsoles Berenguer-Ruiz, Esteban Daudén, Francisco Abad-Santos |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-12-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/13/1/5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacogenetic markers of colorectal cancer treatment. New approaches for cytostatic drugs efficacy estimation
by: N. B. Zakharzhevskaya, et al.
Published: (2015-12-01) -
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
by: Richard B. Warren, et al.
Published: (2024-11-01) -
Pharmacogenetics: Influence of CYP2C9*2 and *3 alleles polymorphisms on Iraqi type 2 diabetic patients
by: Ghada S. Rasool, et al.
Published: (2024-01-01) -
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy
by: Federico Pirro, et al.
Published: (2025-01-01) -
Long-term deprescription in chronic pain and opioid use disorder patients: Pharmacogenetic and sex differences
by: Muriel Javier, et al.
Published: (2023-06-01)